System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish 16 citations

PubMed: 34945186 DOI: 10.3390/jcm10245891

Hydroxyzine Use and Mortality in Patients Hospitalized for COVID-19: A Multicenter Observational Study.

J Clin Med 10(24)

Authors: Marina Sánchez-Rico, Frédéric Limosin, Raphaël Vernet, Nathanaël Beeker, Antoine Neuraz, Carlos Blanco, Mark Olfson, Cédric Lemogne, Pierre Meneton, Christel Daniel, Nicolas Paris, Alexandre Gramfort, Guillaume Lemaitre, Pedro De La Muela, Elisa Salamanca, Mélodie Bernaux, Ali Bellamine, Anita Burgun, Nicolas Hoertel, On Behalf Of Ap-Hp/Université de Paris/Inserm Covid-Research Collaboration/Ap-Hp Covid Cdr Initiative/Entrepôt de Données de Santé Ap-Hp Consortium

Affiliations

  • Département de Psychiatrie, Hôpital Corentin-Celton, AP-HP.Centre-Université de Paris, 92130 Issy-les-Moulineaux, France.
  • Department of Psychobiology & Behavioural Sciences Methods, Faculty of Psychology, Campus de Somosaguas Universidad Complutense de Madrid, 28223 Pozuelo de Alarcon, Spain.
  • Institut de Psychiatrie et Neurosciences de Paris, Université de Paris, UMR_S1266, INSERM, 75014 Paris, France.
  • UFR de Médecine, Faculté de Santé, Université de Paris, 75006 Paris, France.
  • Hôpital Européen Georges Pompidou, Medical Informatics, Biostatistics and Public Health Department, AP-HP.Centre-Université de Paris, 75015 Paris, France.
  • Unité de Recherche Clinique, Hopital Cochin, Assistance Publique-Hopitaux de Paris, 75004 Paris, France.
  • Cordeliers Research Center, Université de Paris, UMRS 1138, INSERM, 75006 Paris, France.
  • Department of Medical Informatics, Necker-Enfants Malades Hospital, AP-HP, Centre-Université de Paris, 75015 Paris, France.
  • Division of Epidemiology, Services and Prevention Research, National Institute on Drug Abuse, 6001 Executive Boulevard, Bethesda, MD 20852, USA.
  • Department of Psychiatry, New York State Psychiatric Institute, Columbia University, 1051 Riverside Drive, Unit 69, New York, NY 10032, USA.
  • Laboratoire d'Informatique Médicale et d'Ingénierie des Connaissances en e-Santé, UMR 1142, INSERM, Sorbonne Université, Université Paris 13, 93017 Paris, France.
  • AP-HP, DSI-WIND (Web Innovation Données), 75184 Paris, France.
  • Laboratoire d'Informatique Médicale et d'Ingénierie des Connaissances en e-Santé, Sorbonne University, University Paris 13, Sorbonne Paris Cité, INSERM UMRS 1142, 75012 Paris, France.
  • LIMSI, CNRS, Université Paris-Sud, Université Paris-Saclay, 91405 Orsay, France.
  • Institut National de Recherche en Sciences et Technologies du Numérique (INRIA), Université Paris-Saclay, INRIA, CEA, 75012 Palaiseau, France.
  • Banque Nationale de Données Maladies Rares (BNDMR), Campus Picpus, Département WIND (Web Innovation Données), AP-HP, 75012 Paris, France.
  • Direction de la Stratégie et de la Transformation, AP-HP, 75004 Paris, France.
  • Unité de Recherche Clinique, Hôpital Cochin, AP-HP, Centre-Université de Paris, 75014 Paris, France.

Abstract

(1) Background: Based on its antiviral activity, anti-inflammatory properties, and functional inhibition effects on the acid sphingomyelinase/ceramide system (FIASMA), we sought to examine the potential usefulness of the H1 antihistamine hydroxyzine in patients hospitalized for COVID-19. (2) Methods: In a multicenter observational study, we included 15,103 adults hospitalized for COVID-19, of which 164 (1.1%) received hydroxyzine within the first 48 h of hospitalization, administered orally at a median daily dose of 25.0 mg (SD = 29.5). We compared mortality rates between patients who received hydroxyzine at hospital admission and those who did not, using a multivariable logistic regression model adjusting for patients' characteristics, medical conditions, and use of other medications. (3) Results: This analysis showed a significant association between hydroxyzine use and reduced mortality (AOR, 0.51; 95%CI, 0.29-0.88, = 0.016). This association was similar in multiple sensitivity analyses. (4) Conclusions: In this retrospective observational multicenter study, the use of the FIASMA hydroxyzine was associated with reduced mortality in patients hospitalized for COVID-19. Double-blind placebo-controlled randomized clinical trials of hydroxyzine for COVID-19 are needed to confirm these results, as are studies to examine the potential usefulness of this medication for outpatients and as post-exposure prophylaxis for individuals at high risk for severe COVID-19.

MeSH

Mortality, Post-Exposure Prophylaxis, Hydroxyzine, Covid-19, Sars-Cov-2

Cited by